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ABSTRACT
Introduction: Blood donation should be voluntary, anonymous and altruistic, and the 
donor should not, directly or indirectly, receive any remuneration or benefit by virtue of 
donating blood. Like any other therapeutic method, transfusion procedures are not risk 
free and can expose the patient to a several complications. Serological screening is 
of great importance to ensure transfusion safety. The present study aimed to estimate 
the prevalence of serological ineligibility among blood donors from a Hemotherapy 
Center in Caxias do Sul (RS).
Method: An exploratory, descriptive and quantitative study was conducted on data 
from July 2010 to December 2015 collected at a Hemotherapy Center in Caxias do 
Sul (RS).
Results: During the study period, 14,267 blood donors attended the Hemotherapy 
Center, of which 9,332 (65.40%) were males and 4,935 (34.60%) were female. 
Considering only the suitable donors, 12,702 blood donations were performed, 
144 (1.13%) presented positive serological tests. The most prevalent positive serology 
was for hepatitis B (anti-HBc) with 98 cases (0.77%), followed by syphilis with 19 cases 
(0.15%); Chagas disease, with 10 (0.08%); hepatitis C, with nine (0.07%); and HIV 
and HTLV, with four (0.03%) reactive samples each.
Conclusion: The results presented are important for health surveillance and make 
it possible to take measures to ensure safe blood stocks.
Keywords: Serology; blood donors; communicable diseases
Blood donation should be voluntary, anonymous, and altruistic; moreover, 
the donor should not, directly or indirectly, receive any remuneration, according 
to the current Brazilian legislation1. Hemotherapy is a therapeutic treatment 
consisting of blood transfusion or transfusion of blood products2. Blood 
donation should be performed by specialized professionals and must strictly 
fulfill several criteria to ensure blood transfusion safety. For example, donors 
must comply with certain mandatory requirements set forth by law, such as 
being from 16 to 69 years, 11 months, and 29 days of age, and providing 
written formal consent from the legal guardians of donor candidates aged 
16 and 17 years for every blood donation. The maximum age threshold for 
first donation is 60 years, 11 months, and 29 days of age. The maximum 
frequency allowed is four blood donations per year for men and three donations 
per year for women, and the minimum interval between donations should be 
2 months for men and 3 months for women. Additionally, donor candidate 
must weight at least 50 kg and have good health. Besides meeting these 
requirements, donor candidates must be assessed throughout the different 
stages of blood donation, including pre-screening, clinical screening, and 
serological screening. Blood donation in Brazil is regulated by Ordinance No. 
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158, dated of February 4, 2016, which determines the 
Sanitation Regulation for Hemotherapy Centers, which 
develop activities related to transfusion procedures 
and to the production cycle of human blood and 
blood components1,3.
The blood transfusion cycle starts with blood 
collection from donor candidates and continues with 
pre-screening, clinical screening, and laboratory 
screening. Reducing the possibility of transmitting 
infectious agents through blood transfusion requires 
measures to ensure its safety4. The current legislation 
establishes that all country’s Hemotherapy Centers 
must perform serological tests to detect markers of 
hepatitis B (anti-HBc/HbsAg), hepatitis C (anti- HCV), 
syphilis (Venereal Disease Research Laboratory, 
VDRL), AIDS (anti-HIV 1 and 2/Western blot), 
HTLV (anti-HTLV I and II), and Chagas disease 
(immunoenzymatic assay, EIA)1.
A study of 60,211 blood donations performed 
in the Caxias do Sul Blood Bank, southern Brazil, 
from 2001 to 2005 found that 1,485 (2.50%) of 
these donations were discarded due to serological 
ineligibility, with the most prevalent marker being 
anti-HBc (1.67%), followed by VDRL (0.65%)5. 
The disposal of these ineligible blood bags during 
screening leads to substantial but necessary costs 
to achieve transfusion safety. Therefore, serological 
screening of blood donors is extremely important 
to prevent the dissemination of blood transmitted 
infectious microorganisms.
The present study aimed to investigate the 
prevalence of serological markers of hepatitis B, 
hepatitis C, AIDS, HTLV I/II, syphilis, and Chagas 
disease among blood donors attending a Hemotherapy 
Center in Caxias do Sul, southern Brazil, from July 
2010 to December 2015.
METHODS
An exploratory, descriptive and quantitative study 
was conducted at a Hemortherapy Center in Caxias do 
Sul, southern Brazil. Firstly, the institution’s database 
was searched for data on donor candidates with 
positive screening for the selected markers from July 
2010 to December 2015. Subsequently, data were 
organized using Microsoft Office Excel 2007 for the 
creation of graphs and tables.
RESULTS
From July 2010 to December 2015, 14,267 
donor candidates attended the Hemotherapy Center 
in Caxias do Sul, southern Brazil, of which 9,332 
(65.40%) were male and 4,935 (34.60%) were female. 
Of the total number of candidates, 14,242 underwent 
clinical screening to ensure recipient’s safety, of 
which 13,217 (92.80%) were considered clinically 
eligible for blood donation and 1,025 (7.20%) were 
considered ineligible.
Eligible candidates had their blood collected, 12,702 
of which donated a full blood bag and had their blood 
samples screened for serological markers. Of the 
12,702 donations, 12,558 were released for transfusion 
(serologically eligible) and 144 (1.13%) were discarded 
(serologically ineligible). The most prevalent positive 
serology was for hepatitis B (anti-HBc and HbsAg), 
with 98 cases (0.77%); followed by syphilis (VDRL), 
with 19 cases (0.15%); Chagas disease (EIA), with 
10 cases (0.08%); hepatitis C (anti-HCV), with nine 
cases (0.07%); and HIV (anti-HIV 1 and 2/Western 
Blot) and HTLV (anti-HTLV I and II), with four (0.03%) 
positive samples each (table 1). The findings presented 
in Figure 1 showed that, during the study period, 
the prevalence of hepatitis B among blood donors 
significantly increased over the years.
Table 1: Annual distribution of positive results for serological markers in an Hemotherapy Center.
Positive 
serological 
screening
2010
794 (100%)
2011
1778 (100%)
2012
2027 (100%)
2013
2718 (100%)
2014
2782 (100%)
2015
2606 (100%)
TOTAL
n (%)
Chagas 
disease (EIA) 0 (0.0%) 3 (0.17%) 4 (0.20%) 2 (0.07%) 0 (0.0%) 1 (0.04%) 10 (0.08%)
Anti-HBc / 
HbsAg 2 (0.25%) 3 (0.17%) 15 (0.74%) 22 (0.80%) 22 (0.80%) 34 (1.30%) 98 (0.77%)
Anti-HCV 0 (0.0%) 3 (0.17%) 4 (0.20%) 0 (0.0%) 0 (0.0%) 2 (0.08%) 9 (0.07%)
Anti-HIV 1 and 
2/Western Blot 0 (0.0%) 3 (0.17%) 0 (0.0%) 1 (0.04%) 0 (0.0%) 0 (0.0%) 4 (0.03%)
Anti-HTLV I/II 0 (0.0%) 0 (0.0%) 1 (0.05%) 1 (0.04%) 0 (0.0%) 2 (0.08%) 4 (0.03%)
VDRL 0 (0.0%) 1 (0.05%) 1 (0.05%) 3 (0.11%) 5 (0.18%) 9 (0.34%) 19 (0.15%)
Total 2 (0.25%) 13 (0.73%) 25 (1.23%) 29 (1.06%) 27 (0.97%) 48 (1.84%) 144 (1.13%)
EIA: Immunoenzymatic assay; Anti-HBc: Detects the presence of the antibody against chorion (a protein that is present in the nucleus of the 
hepatitis B virus); HbsAg: Detects surface antigens of the hepatitis B virus; Anti-HCV: Detects the presence of antibodies against the hepatitis 
C virus; Anti-HIV1 and 2: Detects the presence of antibodies against the HIV 1 and 2 viruses; Anti-HTLV I/II: Detects the presence of antibodies 
against the HTLV I/II viruses; VDRL: Veneral Disease Research Laboratory. A non-treponemal test to detect syphilis.
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DISCUSSION
Pretransfusion stages, such as donor’s recruitment 
and selection, along with serological screening tests, 
reduce the possibility of transfusion transmission 
of infectious microorganisms but is not free of risk 
for recipients. During the study period, there was a 
higher prevalence of male donor candidates in the 
Hemotherapy Center in Caxias do Sul, southern 
Brazil, from July 2010 to December 2015. The lower 
prevalence of female candidates may be explained by 
the fact that some women do not reach the minimum 
weight for donating blood or by the occurrence of 
anemia in women during reproductive age and after 
the menstrual period, thus compromising attendance 
of women to the Hemotherapy Center4. Moreover, 
the higher prevalence in the male gender may be 
explained by the fact that current legislation establishes 
a maximum frequency of four donations per year 
for men and three donations per year for women1. 
Our results are consistent with those of a study that 
found a higher prevalence of male donors in the 
Caxias do Sul Blood Bank (69.10%)5. In another 
study conducted in Maringá, southern Brazil, with 
93,490 donor candidates, the percentage of male 
donors was 61.54%6. Similarly, males accounted 
for 57.00% of blood donations performed in Porto 
Alegre, southern Brazil, from 2013 to 20147.
The disposal rate is related to the importance of 
serological screening to prevent infectious disease 
transmission through blood transfusion. Hepatitis B, 
an infection transmitted by blood transfusion, is 
considered a public health problem, because of the 
high rates of serological disposals due to positive 
serological results8. In the present study, the overall 
disposal rate due to positive serological results was 
144 donations (1.13%), with markers for hepatitis B 
(anti-HBc) and syphilis (VDRL) being the most 
prevalent during the study period, as described 
in Table 1. These findings are in line with those of 
studies conducted in other Brazilian states and cities, 
as shown in Table 2 . In Porto Alegre, Brazil, the 
most prevalent positive serology among blood donor 
candidates was for hepatitis B, with 1,774 (1.97%) 
cases in 2013 and 1,603 (1.82%) in 2014, followed 
Table 2: Comparison of seroprevalence among blood donors in different Hemotherapy Centers in Brazil.
Serologically ineligible donors
City/state Blood donations N % Authors
Chagas Disease
Caxias do Sul/RS 12.702 10 0.08% *
Santa Maria/RS 25.207 246 0.98% Cogo et al.9
Recife/PE 204.124 31 0.02% Sabino et al.10
São Paulo/SP 49.541 19 0.04% Ferreira et al.11
Hepatitis B
Caxias do Sul/RS 12.702 98 0.77% *
Alfenas/MG 25.034 347 1.39% Diogo et al.12
Porto Alegre/RS 88.201 1,603 1.81% Trevizan and Cavada7
Barra das Garças/MT 1.607 91 5.66% Delmondes et al.13
Erechim/RS 2.108 119 5.60% Sbeghen and Paraboni14
Hepatitis C
Caxias do Sul/RS 12.702 9 0.07% *
Uberaba/MG 218.871 814 0.37% Josahkian et al.15
Anápolis/GO 13.633 12 0.09% Costa et al.16
Campo Mourão/PR 25.044 96 0.38% Alves and Isolani17
HIV
Caxias do Sul/RS 12.702 4 0.03% *
Cruz Alta/RS 280 15 5.4% Martins et al.18
Maringá/PR 93.490 46 0.05% Pereira and Bonafé6
Pernambuco 106.203 217 0.20% Queiroz et al.19
HTLV
Caxias do Sul/RS 12.702 4 0.03% *
Piauí/PI 233.927 400 0.17% Oliveira et al.20
Ceará 679.610 164 0.02% Gomes and Eleutério21
Uberaba/MG 147.489 36 0.02% Lima et al.22
Syphilis
Caxias do Sul/RS 12.702 19 0.15% *
Cruz Alta/RS 6.139 37 0.60% Martins et al.18
Goiás 389.424 2,364 0.61% Rodrigues23
Montes Claros/MG 82.743 343 0.41% Magalhães et al.24
Porto Alegre/RS 88.201 819 0.92% Trevizan and Cavada7
*Data found in this study.
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by syphilis, with 702 (0.78%) and 819 (0.93%) cases 
respectively7. According to Ramos and Ferraz25, the 
most prevalent cases of serological ineligibility in the 
blood center of Campo Mourão, southern Brazil was 
due to hepatitis B, with 275 (71.43%) donors, and 
syphilis, with 43 donors (11.17%), out of a total of 
385 disposals after serological screening.
In the present study, 98 (0.77%) of blood donors had 
positive serology for hepatitis B. In Erechim, southern 
Brazil, the rate of positive serology for hepatitis B 
was 5.6% out of a total of 2,108 blood donors14. In a 
survey of report forms of 25,034 blood donors from 
the Hemotherapy Center da Santa Casa de Alfenas 
(NHSCA), located in Alfenas, southeastern Brazil, 
Diogo et al.12 found 347 (1,83%) positive results for 
the anti-HBc marker from January 2000 to December 
2006. Data from the Fundação Hemoninas show that 
hepatitis B is the main cause of serological ineligibility 
among blood donors, accounting for 1.26% of ineligible 
donations in serological screening26.
According to Hemoprod, the percentage of serological 
ineligibility due to hepatitis B among blood donors in 
Brazil was 1.47% in 2012, with each Brazilian region 
showing different seropositive rates. The northern 
region was the one with the highest prevalence of 
positive hepatitis B serology, with 3.77%, followed 
by the southern region, with 1.94%. In 2013, the 
prevalence of the HBs-Ag marker in Brazil ranged 
from 0.07% in the state of Espírito Santo to 0.43% 
in the state of Paraíba. The state of São Paulo had 
the lowest rate for anti-HBc (0.76%), whereas the 
highest rates were reported in the states of Rondônia 
(4.38%) and Acre (4.33%)27.
According to data from the Epidemiological 
Bulletin of the Brazilian Ministry of Health, there 
were 38,007 confirmed cases of hepatitis B from 
1999 to 2011 in the southern region. In 990 (6.60%) 
of these cases, blood transfusion transmission was 
reported as the possible source/mechanism of 
infection28. In an American study of 217,738 donors, 
the prevalence of positive hepatitis B donors was 121 
(0.06%)29. The high rates of hepatitis B and syphilis 
found in the present study may be explained by the 
current environmental risks, which mainly involve 
unprotected sex, since these two diseases may be 
sexually transmitted. Although there is a vaccine for 
hepatitis B, the number of individuals contaminated 
with HBV has increased, as shown in Figure 1. 
This may be explained by the fact that vaccination 
campaigns are not meeting population demands 
and that these individuals were infected before the 
hepatitis B vaccine was available.
Syphilis is a chronic sexually transmitted infection 
caused by the Treponema pallidum spirochete. The usual 
source of infection is contact with a cutaneous or 
mucosal lesion of a sexual partner contaminated 
with syphilis, but it can also be transmitted during 
pregnancy and via blood transfusion30. In the present 
study, 19 (0.15%) donors were positive for syphilis. 
In Brazil, syphilis is the second leading cause of 
serological ineligibility among blood donors, with 
a prevalence of 0.67%. The northeastern region 
had the highest prevalence, with 0.97% of positive 
cases, followed by the southern region, with 0.67%. 
The prevalence ranges of syphilis from 0.13% in the 
state of Rondônia to 2.42% in the state of Maranhão, 
with Rondônia presenting the lowest positivity rate for 
syphilis but the highest prevalence for the anti-HBc 
marker27.
Screening methods to detect syphilis include 
non-treponemal tests, such as the VDRL test, and 
diagnosis should be confirmed with treponemal 
tests such as the microhemagglutination assay for 
Treponema pallidum or the fluorescent treponemal 
Figure 1: Annual prevalence of positive serology for hepatitis B markers.
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antibody-absorption test1. A study assessing the 
prevalence of serological ineligibility due to syphilis in 
a Hemotherapy Center in Cruz Alta, southern Brazil, 
from 2003 to 2009 found 60 (0.03%) VDRL positive 
cases out of a total of 20.780 medical records31. 
According to Rodrigues, there were 389,424 blood 
donations in the Goiás Blood Center, midwestern 
Brazil, from January 2002 to December 2011, 2,364 
(0.61%) of which were positive for the VDRL marker23. 
In the state of Santa Catarina, the seroprevalence of 
syphilis was 81.3 per 100,000 inhabitants (0.08%) 
from January to December 201032. In Montes Claros, 
southeastern Brazil, positive results for the VDRL 
marker was the most prevalent reason for serological 
ineligibility, with 243 (0.41%) cases out of a total of 
82,743 blood donors24.
Chagas disease is known to be an endemic 
infection in some regions of South America and Brazil; 
therefore, serological screening of blood donors is 
essential, since this disease may be transmitted by 
blood transfusion. Chagas disease is an infection 
caused by the protozoan parasite Trypanosoma cruzi 
and transmitted by the infected stool of hematophagous 
triatomine insects. Other means of contamination 
include vertical transmission, oral transmission, 
and organ transplantation33. Currently, screening 
for Chagas disease in Hemotherapy Centers is 
performed by detecting anti-T.cruzi antibodies using 
EIA or chemiluminescence1. In the present study, 
positive serological results for Chagas disease were 
found in 10 donors (0.08%). In 2012, serological 
ineligibility rate for blood donation due to Chagas 
disease was 0.26%, according to data from the 
Annual Hemotherapy Production Bulletin. This bulletin 
also reports that the prevalence of Chagas disease 
in Brazil ranged from 0.02% in the state of Espírito 
Santo to 0.54% in the state of Rio de Janeiro27. In an 
analysis of 25,207 blood donations performed in the 
Hematology Unit of Hospital Universitário de Santa 
Maria, southern Brazil, from January 2004 to December 
2007, Cogo et al.9 found that 246 (0.98%) donors 
presented a positive or indeterminate serology for 
Chagas disease. The prevalence of positive serology 
for Chagas disease may be explained by the higher 
number of individuals who had not sought other health 
care services yet and whose disease had not been 
detected before, since it is usually asymptomatic, by 
the high rate of migration from rural to urban areas, 
and by improvements in housing, educational, and 
health conditions34,35.
Serological screening for hepatitis C is performed 
by two tests: detection of anti-HCV antibodies or 
combined detection of anti-HCV antibodies and 
HCV antigens; and detection of HCV nucleic acid1. 
In the present study, 9 (0.07%) donors were positive 
for hepatitis C. In 2012, the ineligibility rate due to 
hepatitis C among blood donors was 0.27% in Brazil, 
ranging from 0.09% in the state of Tocantins to 0.65% 
in the state of Mato Grosso do Sul27.
There were 18,307 confirmed cases of hepatitis 
C in the southern region from 1999 to 2011. In 3,910 
(32.30%) of these cases, transfusion transmission 
was reported as the possible source/mechanism of 
infection28. Josahkiane et al.15 assessed 218,871 blood 
donations carried out at Hemocentro Regional de 
Uberaba (HRU) from 1995 to 2008, 814 (0.40%) of 
which were ineligible because of positive serological 
test for HCV. The implementation of the nucleic acid 
amplification test in hemotherapy centers has been 
of great help in attempting to minimize risks arising 
from blood transfusions. This test is also mandatory 
for hepatitis C screening, thus reducing the window 
period to 6 or 7 days36.
In the present study, the prevalence of positive 
serology for HIV 1 and 2 and HTLV I and II was 
0.03%, which was the lowest prevalence among all 
the tested serologies. Currently, screening for HIV 
includes serological tests that detect the presence of 
the antibody against HIV or allow for the combined 
detection of antibody against HIV + HIV p24 antigens 
and molecular tests that aim to detect HIV nucleic acid1. 
From 1980 to 2015, 207 HIV cases were reported to 
the Notifiable Diseases Information System (Sistema 
de Informação de Agravos de Notificação, SINAN) 
as the possible source/mechanism of transfusion 
infection37. In 2012, 0.36% of blood donors were 
serologically ineligible due to HIV infection; in the 
southern region, this percentage was 0.28%28. 
HTLV I and II are screened by detecting antibodies 
against HTLV I/II1. In Brazil, the prevalence of 
serological ineligibility due to positive serology for 
HTLV was 0.17% in 2012, with the northeastern 
region showing the highest seropositive rate, with 
0.28%, and the northern region showing the lowest 
rate, with 0.07%27.
There is clearly a significant difference in the 
prevalence of positive serologies among blood donors 
from different Brazilian states. One should bear in mind 
that variations in results may be explained by several 
factors, such as differences in the methodologies 
used and good clinical screening, because when the 
latter is efficiently performed donors with possible 
positive serology are disqualified for blood donation. 
In the present study, hepatitis B and syphilis were the 
main causes of serological ineligibility among blood 
donors and may be related to present-day habits and 
behaviors, which lead to increased risk of contamination. 
Therefore, pre-transfusion measures covering 
recruitment of blood donors, clinical screening, and 
serological screening are of great help in attempting 
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to minimize risks arising from blood transfusions18. 
Considering that microorganisms causing diseases 
such hepatitis B, hepatitis C, HIV, HTLV, syphilis, and 
Chagas disease may be transmitted during transfusion 
and impair recipient’s quality of life, further studies 
are necessary to evaluate the serological profile of 
blood donors. Screening to detect the presence of 
a given blood transmitted microorganism in blood 
bag will contribute to the adoption of more objective 
and early measures to reduce contamination during 
transfusion.
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